Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: WJB001 Capsules+Paclitaxel/Paclitaxel-albuminDrug: WJB001 Capsules+carboplatin/NedaplatinDrug: WJB001 Capsules+Paclitaxel+carboplatinDrug: WJB001 Capsules+NiraparibDrug: WJB001 Capsules+Bevacizumab
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 86
- Registration Number
- NCT06953323
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2025-02-10
- Target Recruit Count
- 210
- Registration Number
- NCT05773820
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
News
No news found